Most early-stage digital health founders don’t have an evidence problem. They have a prioritization problem. They measure what they think will help them sell, satisfy investors, or sound credible instead of what helps them make the next business decision.
The most common evidence mistake in digital health isn’t a lack of evidence. It’s collecting the wrong evidence at the wrong time.
Too often, founders either skip science entirely, or they run a 12-week outcomes study on a product that wasn’t stable enough to produce a clean signal. Both are expensive, and both happen more often than necessary.
When founders do engage with evidence, the study itself is often part of the problem. The hypothesis wasn’t grounded in a real decision the business needed to make. The outcome measure was chosen because it seemed useful for sales or sounded credible in a pitch deck, not because it mapped to what the product actually does. The sample was too small to say anything meaningful, but the results got used in a pitch deck anyway. And when an investor or enterprise buyer pushed on it in diligence, it fell apart.
That’s not bad luck. It’s what happens when evidence is treated as a sales or credibility box to check rather than a tool for reducing uncertainty. Founders who build evidence well aren’t always doing more science. They’re asking better questions earlier, at the right stage, with the right audience in mind.
According to CB Insights, digital health funding rose 19% year over year to $22.3 billion in 2025, but deal volume dropped as average check sizes grew. Capital is concentrating in companies that can demonstrate a clear, credible line from product to outcome. Collecting the wrong evidence at the wrong time doesn’t just waste the budget; it creates a credibility gap at exactly the moment founders can least afford one.
Why Does the Order You Measure Things In Actually Matter?
Evidence works much like product development. You don’t optimize retention before someone can successfully complete onboarding. Evidence follows a similar progression.
Many digital health companies focus on proving outcomes before they’ve established usability, adoption, or product-market fit. That sequencing issue often creates avoidable research costs and weaker evidence later.
Usability and adoption are the foundation. Engagement patterns and early signals are the framing. Clinical or outcomes-level evidence is the roof. Build out of order and the instability shows up later, usually when an investor, payer, or enterprise buyer starts asking questions the data wasn’t designed to answer.
Before choosing what to measure, identify which uncertainty is most blocking progress right now. Not which metric sounds sexy enough to sell, or credible to an outside audience, but which unknown, if resolved, would most change what the team does next. If confirming or rejecting a hypothesis wouldn’t actually change a product, sales, or fundraising decision, it’s the wrong hypothesis to test first.
Here’s a simple way to think about evidence in the first year: start by confirming the product experience works, then clarify the hypothesis, then build evidence around the next commercial door you’re trying to open.
Months 0 to 3: Confirm the Product Can Do What It’s Supposed to Do
Before measuring whether your product improves health outcomes, make sure users can actually use it.
This sounds obvious, but it isn’t always practiced. Most early-stage digital health products have usability gaps that don’t surface in engagement dashboards. They show up in behavior patterns that look fine on the surface but mask confusion, friction, or a mismatch between what the team built and what users understand. A founder might see reasonable session counts and assume the product is working, when users are actually spending that time lost or confused. (Session time is not the same as session value.)
The most valuable evidence in the first three months answers one foundational question: is the product working as a delivery vehicle? Are users completing the actions the product is built around and returning after the first session? Getting signals on where friction lives and what users do in the moments before they drop off reshapes onboarding, content sequencing, and feature prioritization before those decisions get locked in at scale.
Structured customer discovery belongs here too. Not focus groups designed to validate the product, but real inquiry that surfaces behavior rather than reassurance. Early signals from this kind of discovery, patterns that show up repeatedly across multiple conversations, become the raw material from which testable hypotheses get built. Limitations found here aren’t failures. They’re the cheapest, most actionable findings available, and being honest about them is a credibility signal.
This stage is also where many companies discover they are still refining product-market fit. Evidence gathered here often reveals gaps between what teams believe users value and what users actually find useful.
Months 3 to 6: Frame a Hypothesis Before You Design Anything
Once the product is stable and users are engaging meaningfully, the temptation is to move straight to a study. Resist it.
A useful hypothesis has three parts: who it applies to, what you expect to observe, and under what conditions. “Users like our product” is not a hypothesis. “New users who complete the onboarding sequence within the first week are more likely to return for a second session without prompts” is a hypothesis, because its answer would directly change a product decision.
Writing it out this way before touching a survey or running any analysis forces the team to confront whether they’re testing something that actually matters to the business, or just generating data because data feels productive.
With a hypothesis in hand, this window is the right time for informed observation: looking at existing usage and behavioral data to see whether what’s being observed is directionally consistent with the change the product intends to create. The goal isn’t statistical significance; it’s map-making. Which segments show the strongest early signals? Where does drop-off cluster relative to the intended benefit? If results are consistent, that’s worth building on. If they’re mixed, adjust before investing in something more formal. If there’s no signal at all, that’s a meaningful pause point, not a reason to run a bigger study and hope for different results.
Months 6 to 12: Build Evidence for the Specific Door You’re Trying to Open
By seed stage, evidence needs to reduce uncertainty for external stakeholders, and the right evidence type is almost entirely determined by commercial pathway, not by what sounds most rigorous in the abstract.
Employer channels need workforce-relevant evidence: absenteeism, care utilization, or productivity data that connects to cost. Benefits leaders and CFOs aren’t evaluating clinical elegance. The companies that have moved fastest in this channel have learned to translate clinical language into business impact language, because that’s what the room is actually listening for.
Payer conversations require evidence tied to total cost of care and utilization. Payers are asking one question: will reimbursing this reduce what we spend? Evidence that doesn’t speak to that, regardless of how strong it is clinically, typically stalls at the contracting stage.
Provider and health system partnerships require clinical plausibility and peer-reviewed support, but also practical workflow evidence. A study demonstrating strong outcomes in an ideal research setting is less persuasive to a clinical partner than evidence the product works with real patients, at realistic adherence rates, with manageable implementation burden.
Consumer products need accessible, trust-building evidence: clear language about what the product does and for whom, user satisfaction signals, and early outcome data that a non-clinical reader can understand and repeat.
Four different buyers, four different definitions of proof. Many founders assume evidence becomes more valuable as it becomes more rigorous. In reality, evidence becomes more valuable when it answers the question the buyer is actually asking.
Choosing the most important commercial milestone for the next twelve months and building evidence specifically around that decision is the most efficient move available, and it produces a more persuasive story because the evidence is designed to reduce the exact uncertainty the buyer is feeling.
What Does Getting the Evidence Sequence Right Actually Look Like?
A founder who sequences evidence well in year one doesn’t necessarily have more data. They have better-positioned data.
Consider two companies at the same stage, both approaching a Series A. The first ran a usability study at month two, fixed a core onboarding gap, then ran a behavioral analysis at month five that revealed which feature cohort showed the strongest early outcome signal. By month ten, they had a targeted pilot designed specifically around employer buyer questions. When the investor asked for evidence in diligence, the answer was already prepared.
The second company skipped straight to a 12-week outcomes study at month four. The results were positive but inconclusive. Engagement was too variable to isolate the effect. The data sat in a deck. The investor asked follow-up questions the study wasn’t designed to answer. The team went back to design another study.
Same commitment to evidence. Different sequence. Very different outcome.
What Happens After Month 12?
The first 12 months are not the whole evidence strategy. They are the foundation for what comes next.
After year one, the work usually shifts from “What should we measure first?” to “What evidence do we need to support the next stage of growth?” That may mean a larger feasibility study, formal outcomes study, claims substantiation, health economic analysis, peer-reviewed publication, payer-facing evidence, implementation data, or a stronger evidence story for Series A or Series B.
The right next step depends on the door the company is trying to open. A company preparing for enterprise sales may need stronger buyer-specific proof. A company moving toward payer conversations may need utilization or cost-related evidence. A company seeking clinical partnerships may need implementation evidence, clinician trust, and patient outcomes. A company preparing for a later fundraising round may need a clearer evidence narrative that connects product behavior, outcomes, and commercial potential.
The point is not that every company needs to move from early evidence to a clinical trial. The point is that evidence should mature as the company matures. The best year-one evidence makes that next phase easier because the team has already clarified the product, the user, the outcome, and the stakeholder who needs to believe the story.
Build Your Digital Health Evidence Roadmap Before You Need It
The biggest risk in evidence planning is reactivity. Founders who start thinking about measurement only when a buyer asks for proof are always behind. Founders who build a sequenced plan in year one, matched to product maturity, commercial pathway, and the decisions they need to make, rarely find themselves scrambling.
This is why we built the Science Strategy Masterclass for early-stage founders. The goal is not to turn founders into researchers. It is to help them think more clearly about which assumptions carry the most risk, what evidence is worth collecting first, and how to build a roadmap that supports product, fundraising, sales, and credibility without overbuilding too early.
For founders trying to decide what to measure, when to measure it, and how to use early evidence responsibly, the masterclass provides a practical way to start building that roadmap before a buyer, investor, or partner asks for proof.
FAQ: Evidence sequencing for early-stage digital health founders
What should a digital health founder measure first?
Start with product usability and early adoption behavior. Usability gaps that surface in the first 60 days will distort any outcome data collected before they’re addressed. Before choosing what to measure, identify which uncertainty is most blocking progress and whether resolving it would actually change a business decision.
Do early-stage health startups need clinical trials in year one?
Rarely. In year one, feasibility signals, behavioral data, and early outcome indicators are more actionable and achievable than clinical trials, which are most valuable once a product’s delivery model is stable and a specific commercial or regulatory pathway requires that level of rigor.
Why does commercial pathway determine what evidence to collect?
Because different buyers evaluate different kinds of uncertainty. Evidence designed for an investor doesn’t automatically translate to a payer. Evidence designed for a payer rarely moves a consumer. Getting specific about who needs to be convinced, and of what, is what makes evidence useful rather than just credible.
What is a digital health evidence roadmap?
A digital health evidence roadmap is a structured plan that sequences evidence generation around business decisions rather than academic convention. It identifies which assumptions carry the most risk, what evidence reduces that risk, and which stakeholders need to find it credible for the company to move forward.
When is the right time to invest in a formal outcomes study?
When the product delivery model is stable, early behavioral signals suggest the mechanism is working, and a specific commercial milestone requires it. Running a formal outcomes study before those conditions are met typically produces ambiguous data that costs time and budget without advancing the business.
Build the right evidence at the right time—let’s create your roadmap.